Krognes Steve E. sold $1.2M of GH

Krognes Steve E. sold 6,674 shares of Guardant Health, Inc. (GH) at an average of $175.74 ($174.46–$177.48, $1.17M total) across 4 trades on 2026-09-16.

Original reporting
SEC EDGAR · Krognes Steve E.
Published Sep 17, 2026, 9:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 9:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$GH
Bearish
medium confidence
Mentioned
$GH
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GHBearishLow
01

Why it matters

The director's sale may be interpreted as a bearish cue, but the modest size limits market reaction.

02

Market read

Primary insider sale filing with modest dollar amount; limited immediate trading impact.

03

What to watch

Recent positive trial data or upcoming earnings could offset the impact of the sale.

Relevance 6/10Novelty 5/10Timing: post‑market 2026-09-16 filing released 2026-09-17

Background

SEC Form 4 filings disclose insider transactions and are considered primary sources of material information.

Company-level read

Ticker impact

$GHBearishMedium confidence
Context

Director Steve Krognes sold 6,674 shares of Guardant Health for $1.17M on 2026-09-16.

Expected impact

Possible modest downside of 1‑2% in the next trading session.

Evidence & confidence

A $1.2M sale by a director is material enough to attract attention, but the amount is modest relative to market cap.

Market effects

Limited impact on the broader biotech sector; insider sales are common and usually company‑specific.

No significant regional effect; the filing is U.S.‑focused.

Minimal global relevance beyond Guardant Health investors.

Counterpoint

The sale could be a routine portfolio rebalancing rather than a negative signal.

Key entities

  • Guardant Health, Inc.

    US‑listed liquid biopsy company (ticker GH).

  • Steve E. Krognes

    Director of Guardant Health who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$GHHighAI 8/10

Why is Guardant Health stock climbing today?

Guardant Health (GH) stock rose 2.5% in pre-market trading after pricing a $500M offering of 0% convertible notes due 2032, with a 35% premium conversion price. The company plans to use proceeds to repurchase $395.2M of existing convertible notes due 2027, optimizing its balance sheet. The move came amid broader market headwinds for growth and tech names.